Your session is about to expire
← Back to Search
Patient-Reported Outcomes After Breast Biopsy
N/A
Waitlist Available
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients treated at DUMC, DFCI, MDACC, MGH, NWH, or DFCI @ SSH with a diagnosis of DCIS, LCIS, ADH, or ALH
Age 18 or more at index diagnosis
Must not have
Ever had a diagnosis of invasive or microinvasive breast cancer
DCIS prior to index lesion or history of progressive/recurrent DCIS after treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up patient reported outcome was scheduled from at least one year from diagnosis. participants' time from diagnosis to completing a survey was an average of 45.8 months in this study cohort.
Awards & highlights
Summary
This trial looks at how women feel after a breast biopsy, focusing on those with certain breast conditions. The goal is to help women and doctors make better care decisions based on these experiences.
Who is the study for?
This trial is for adults who've had a breast biopsy showing atypical lesions and have been treated at certain study sites. They must be able to read English or Spanish, provide consent, and have at least one year of follow-up data post-diagnosis. Those with other cancers within the last five years or invasive breast cancer ever are excluded.
What is being tested?
The PORTAL study is not testing a drug but rather collecting information through surveys on how patients feel physically and emotionally after treatment for specific non-invasive breast conditions like ADH, ALH, LCIS, or DCIS.
What are the potential side effects?
Since this trial involves completing surveys about patient experiences post-treatment rather than testing medications or therapies, there are no direct side effects associated with the interventions being studied.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I was treated for early breast changes at a specified hospital.
Select...
I was 18 or older when my condition was first diagnosed.
Select...
I have had breast conditions in both breasts, either at the same time or at different times.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been diagnosed with invasive or microinvasive breast cancer before.
Select...
I have had DCIS before my current cancer or it came back after treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ patient reported outcome was scheduled from at least one year from diagnosis. participants' time from diagnosis to completing a survey was an average of 45.8 months in this study cohort.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~patient reported outcome was scheduled from at least one year from diagnosis. participants' time from diagnosis to completing a survey was an average of 45.8 months in this study cohort.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
The Measures Severity of Chronic Pain.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Patient-reported Outcomes SurveyExperimental Treatment1 Intervention
The survey will administered online, over the phone, or via mail.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Breast cancer treatments work through various mechanisms to target and eliminate cancer cells. Surgery, including biopsies, physically removes cancerous tissue, which is crucial for diagnosis and reducing tumor burden.
Radiation therapy uses high-energy rays to destroy cancer cells and shrink tumors. Chemotherapy involves drugs that kill rapidly dividing cells, including cancer cells, throughout the body.
Hormone therapy blocks hormones like estrogen that fuel certain breast cancers, while targeted therapy focuses on specific molecular targets, such as HER2, to inhibit cancer growth. These treatments are essential for managing breast cancer, improving survival rates, and tailoring therapy to individual patient needs based on diagnostic findings from procedures like biopsies.
Find a Location
Who is running the clinical trial?
Dana-Farber Cancer InstituteLead Sponsor
1,102 Previous Clinical Trials
357,132 Total Patients Enrolled
144 Trials studying Breast Cancer
21,047 Patients Enrolled for Breast Cancer
Ann H. Partridge, MD, MPHStudy DirectorDana-Farber Cancer Institute
1 Previous Clinical Trials
257 Total Patients Enrolled
1 Trials studying Breast Cancer
257 Patients Enrolled for Breast Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with invasive or microinvasive breast cancer before.I have not been diagnosed with any cancer other than non-melanoma skin cancer in the last 5 years.I was treated for early breast changes at a specified hospital.I was 18 or older when my condition was first diagnosed.I was diagnosed with a specific breast condition between 2012 and 2017.I have had breast conditions in both breasts, either at the same time or at different times.I have had DCIS before my current cancer or it came back after treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Patient-reported Outcomes Survey
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger